Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma

Erlmeier M, Mikuteit M, Zschaebitz S, Autenrieth M, Weichert W, Hartmann A, Steffens S, Erlmeier F (2023)


Publication Type: Journal article

Publication year: 2023

Journal

Book Volume: 23

Article Number: 90

Journal Issue: 1

DOI: 10.1186/s12894-023-01263-0

Abstract

Background: The prognostic value of Hepatocyte growth factor (HGF) in non-clear cell renal cell carcinoma (RCC) is still unclear. The aim of this study is to evaluate the prognostic impact of HGF expression in a large cohort of chromophobe RCC (chRCC). Methods: Patients who underwent renal surgery due to chRCC were recruited. Clinical data was retrospectively evaluated. Tumor specimen were analyzed for HGF expression by immunohistochemistry. Results: 81 chRCC patients were eligible for analysis, thereof 37 (45.7%) patients were positive for HGF. No significant associations were found for HGF expression and clinical attributes in patients with chRCC. Kaplan-Meier analysis revealed no differences in 5-year overall survival (OS) for patients with HGF compared to HGF+ tumors (95.0% versus 90.9%; p = 0.410). Conclusions: In chRCC HGF expression is not associated with parameters of aggressiveness or survival.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Erlmeier, M., Mikuteit, M., Zschaebitz, S., Autenrieth, M., Weichert, W., Hartmann, A.,... Erlmeier, F. (2023). Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma. BMC Urology, 23(1). https://doi.org/10.1186/s12894-023-01263-0

MLA:

Erlmeier, Maximilian, et al. "Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma." BMC Urology 23.1 (2023).

BibTeX: Download